The specific FAK inhibitor, PGN-118647, was used to break down FAK at tyrosine 397, resulting in G0/G1 pause, apoptosis, downregulation of enhancer of Zeste homolog 2 (EZH2), and upregulation of Notch homolog 2 (NOTCH2) to inhibit HCC cell growth [26]. Here, EZH2 is linked to hepatocellular carcinoma.